Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Bactiguard Holding AB's revenue per share for the
three
months ended in Jun. 2026 was kr1.54.
Bactiguard Holding AB's revenue per share for the trailing twelve months (TTM) ended in Jun. 2026 was kr5.85.
Warning Sign:
Bactiguard Holding AB revenue per share has been in decline over the past 3 years.
During the past 12 months, the average Revenue Per Share Growth Rate of Bactiguard Holding AB was -13.70% per year.
During the past 3 years, the average Revenue Per Share Growth Rate was -1.60% per year.
During the past 5 years, the average Revenue Per Share Growth Rate was 5.50% per year.
During the past 10 years, the average Revenue Per Share Growth Rate was 5.90% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get other companies' revenue growth rate.
The historical rank and industry rank for Bactiguard Holding AB's Revenue per Share or its related term are showing as below:
CHIX:BACTBs'
s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: -93.4 Med: 3.4 Max: 15.9
Current: -1.6
During the past 13 years, Bactiguard Holding AB's highest 3-Year average Revenue Per Share Growth Rate was 15.90% per year. The lowest was -93.40% per year. And the median was 3.40% per year.
CHIX:BACTBs's 3-Year Revenue Growth Rate is ranked worse than 62.32% of 759
companies
in the Medical Devices & Instruments industry
Industry Median: 3.7
vs CHIX:BACTBs: -1.60
His favorite companies are stalwart, those growing between 10-20% a year.
Companies in cyclical industries may see their revenue fluctuate wildly in good years and bad years.
Be Aware
Revenue can be manipulated by changing the way how revenue is booked. Companies may book sales before the payment is received, or before the revenue is fully earned. These will be added to balance sheet items such as account payable or account receivables.
Bactiguard Holding AB Revenue per Share Related Terms
Bactiguard Holding AB Revenue per Share Historical Data
* Premium members only.
The historical data trend for Bactiguard Holding AB's Revenue per Share can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CHIX:BACTBS vs ABT, SYK, MDT: Revenue per Share Comparison
For the Medical Devices subindustry, Bactiguard Holding AB's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Bactiguard Holding AB PS Ratio vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Bactiguard Holding AB's PS Ratio distribution charts can be found below:
* The bar in red indicates where Bactiguard Holding AB's PS Ratio falls into.
Bactiguard Holding AB Revenue per Share Calculation
Revenue per Share is the amount of Revenue per outstanding share of the company's stock.
Also referred as sales, revenue is income that a company receives from its normal business activities, usually from the sale of goods and services to customers. Revenue is often referred to as the "top line" due to its position on the income statement at the very top.
Bactiguard Holding AB's Revenue Per Share for the fiscal year that ended in Dec. 2025 is calculated as
Revenue per Share for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was kr5.85
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Bactiguard Holding AB (CHIX:BACTBS) has a Revenue per Share of kr5.85 as of Jun. 2026. Revenue per share equals the per-share value of a company's sales. View historical data on Bactiguard Holding AB and its competitors. According to the industry distribution chart, Bactiguard Holding AB ranks #473 out of 759 companies in the Medical Devices & Instruments industry, placing it in the top 62.3%.
Is Bactiguard Holding AB's Revenue per Share too high?
Bactiguard Holding AB's current Revenue per Share is kr5.85. Based on the distribution chart, Bactiguard Holding AB ranks #473 out of 759 companies in the Medical Devices & Instruments industry, which is below the industry midpoint. Overall, Bactiguard Holding AB has a GF Score™ of 60/100, reflecting its overall financial health beyond just this single metric.
How does Bactiguard Holding AB's Revenue per Share compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Bactiguard Holding AB ranks #473 out of 759 companies for Revenue per Share. This places Bactiguard Holding AB in the lower half of its industry. The industry median Revenue per Share is 3.70. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Revenue per Share for a Medical Devices & Instruments company?
The median Revenue per Share among Medical Devices & Instruments companies is 3.70, based on 759 companies in the industry. Companies in the top quartile (top 25%) have a Revenue per Share significantly above this median, while those in the bottom quartile fall well below. However, Revenue per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Revenue per Share mean?
A high Revenue per Share can signal that a stock is expensive relative to its fundamentals. Revenue per share equals the per-share value of a company's sales. View historical data on Bactiguard Holding AB and its competitors. For the Medical Devices & Instruments industry, the median Revenue per Share is 3.70 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Bactiguard Holding AB's current Revenue per Share is kr5.85. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Bactiguard Holding AB stock overvalued right now?
Bactiguard Holding AB (CHIX:BACTBS) has a current Revenue per Share of kr5.85. The stock's GF Value™ is kr240.32, compared to a current price of kr128.60 — trading 46.5% below its estimated fair value. The current Revenue per Share is kr5.85. Bactiguard Holding AB's overall GF Score™ is 60/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Revenue per Share calculated?
Revenue per Share is calculated from a company's financial statements. For Bactiguard Holding AB (CHIX:BACTBS), the current Revenue per Share is kr5.85 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Bactiguard Holding AB (CHIX:BACTBS) Overvalued in 2026?
Based on GuruFocus' analysis, Bactiguard Holding AB stock appears to be undervalued.
The current stock price of kr128.60 is trading 46.5% below its estimated GF Value™ of kr240.32.
Key valuation signals for CHIX:BACTBS:
Revenue per Share: kr5.85
GF Value™: kr240.32 vs. price of kr128.60 (46.5% below fair value)
No single metric tells the full story. See the CHIX:BACTBS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Bactiguard Holding AB is a medical device company. It is engaged in a MedTech company developing safe and biocompatible technology to prevent medical device-related infections. The technology is based on an ultra-thin noble metal coating that prevents bacterial adhesion and biofilm formation on medical devices. The company focuses on five strategic therapeutic areas wherein infection rates create high medical needs for infection prevention. These areas include Orthopedics, Cardiology, Neurology, Urology, and Vascular Access. Geographically, the company operates in the USA, Malaysia, China, Saudi Arabia, Bangladesh, Sweden, the Czech Republic, and Other countries. The majority of its revenue is generated from the USA region.
60GF Score
Get the complete analysis for CHIX:BACTBS
Revenue per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CHIX:BACTBS has been successfully added to your 
